SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the main focus, with traders debating whether guidance can clear a high bar as AI-linked stocks face pressure. Some expect strong growth to support the shares, while others warn that even a beat may disappoint given the valuation; the stocks recent decline has sharpened that divide.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracles shares have sharply reversed an Investor Day rally, with traders focused on whether its AI infrastructure backlog can justify heavy spending and debt despite managements cash-flow and capital-discipline outlook. The debate is split between bulls who view the buildout as a long-term growth opportunity and bears who question customer funding, backlog conversion, and the stocks weakness amid broader tech-sector pressure.

Cash Cat (CASHCAT) is a cryptocurrency launched in 2026and operates on the Robinhood Chain platform. Cash Cat has a current supply of 1,000,000,000. The last known price of Cash Cat is 0.0938856 USD and is up 2.53 over the last 24 hours. It is currently trading on 318 active market(s) with $8,318,268.61 traded over the last 24 hours. More information can be found at https://cashcattoken.xyz/.

Cash Cat

Cash Cat is drawing attention after a sharp, volatile rally on the Robinhood network, with traders pointing to exchange listingsincluding Upbitas a catalyst and watching for further momentum. Bullish holders frame dips as accumulation and speculate about a short squeeze, while skeptics call the moves pump-and-dump behavior and warn that gains have repeatedly faded.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces announced acquisition of customer-engagement software company Braze has put the stock under pressure, with traders questioning the cost and potential returns while others see a strategic boost to its AI and marketing products. The deal debate is unfolding against broader concerns that AI could disrupt traditional SaaS businesses.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to a 52-week high has traders focused on the upcoming Q3 report and whether BRIUMVIs sales momentum will support the companys growth outlook. Bullish call-option activity and high-short-interest chatter are fueling squeeze speculation, while buyout talk remains unconfirmed.

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Liquidia Corp

Liquidias settlement with United Therapeutics resolved the companies pending lawsuits and keeps YUTREPIA on the market for PAH, while giving up the PH-ILD indication. Traders are reacting to the reduced risk of a broader sales interruption with optimism about a rebound and potential short covering, while others focus on the lost market opportunity and substantial settlement payments as risks to future growth and cash.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,180,209.38070502. The last known price of Ethereum is 2,270.17304981 USD and is up 0.59 over the last 24 hours. It is currently trading on 14230 active market(s) with $5,193,092,001.43 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Discussion centers on the reported multibillion-dollar Binance hack and its potential spillover to Ethereum and broader crypto markets. Traders are split between fearing further selling and lost exchange confidence, and viewing the selloff as a buying opportunity amid claims Binance will cover customer losses.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Discussion centers on claims that POET optical engines were featured in Foxconns photonics ecosystem, which traders view as validation of the existing FIT collaboration and possible precursor to purchase orders. Others caution that a demo does not establish commercial shipments, and frustration over limited order and revenue disclosures is prominent as investors look to earnings for evidence of execution.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

Discussion centers on broad-market volatility and the Dows relative strength versus tech-heavy indexes, with traders debating whether the Dow can hold support or join a broader decline. Macro concernsincluding rising yields, inflation, and Iran-related oil and geopolitical riskscompete with bullish calls for a continued rally.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is being swept up in a semiconductor selloff as traders question whether hyperscalers heavy AI spending can generate adequate returns and worry that any capex slowdown could hit custom-chip orders. Some see AVGO as collateral damage despite ongoing AI commitments, including Anthropic-related demand, while others argue its concentrated customer base leaves it exposed if spending falters.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical

Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial...

MeiraGTx Holdings PLC (MGTX) Q2 Earnings and Revenues Surpass Estimates

MeiraGTx (MGTX) delivered earnings and revenue surprises of +538.46% and +20,637.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of +20.69% and -61.78%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia

Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia PR Newswire NEW YORK, Aug. 11, 2026 Graviton...

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +27.27% and -9.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

Pacira (PCRX) delivered earnings and revenue surprises of +14.06% and +1.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

uniQure (QURE) delivered earnings and revenue surprises of -50.62% and -17.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts See a 128.14% Upside in MeiraGTx (MGTX): Can the Stock Really Move This High?

The mean of analysts' price targets for MeiraGTx (MGTX) points to a 128.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

MeiraGTx (MGTX) Moves 5.5% Higher: Will This Strength Last?

MeiraGTx (MGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

MeiraGTx Enters $400 Mln Investment Deal With Oberland Capital

(RTTNews) - MeiraGTx Holdings plc (MGTX), a clinical-stage genetic medicine company, on Tuesday entered into an agreement with Oberland Capital Management for an investment of up to $400 million...

MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It targets local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet needs. The company was founded on March 20, 2015 and is headquartered in New York, NY.

MeiraGTx Holdings plc

MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle?

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>MeiraGTx will receive an upfront payment of $75 million and will be eligible to receive over $400 million in total milestone payments in addition to tiered royalties on licensed products.&nbsp;</li><li>Lilly, meanwhile, will also receive worldwide exclusive access rights to MeiraGTx’s gene therapy technologies for use in ophthalmology.</li></ul>Shares of genetic medicines company MeiraGTx Holdings plc (MGTX) soared as much as 13% on Monday after the company announced a strategic collaboration with Eli Lilly and Company (LLY) in the eye diseases segment.As part of the collaboration, MeiraGTx will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-enters-strategic-collaboration-eli-lilly-and-company">grant</a> Lilly worldwide exclusive rights to its AAV-AIPL1 program for the treatment of Leber congenital amaurosis 4 (LCA4). Leber congenital amaurosis 4 is a severe, inherited eye disease that causes significant vision loss from birth. Symptoms include involuntary eye movements, sensitivity to light, high hyperopia, and a cone-shaped cornea.Following treatment with AAV-AIPL1, 11 children who were born blind gained vision, the company said, while adding that the treatment also resulted in benefits in vital areas of development, including communication, behavior, learning, mood, psychological benefits, and social integration.<h2 class="st-heading-2">Terms Of The Collaboration</h2>Lilly will also receive worldwide exclusive access rights to MeiraGTx’s gene therapy technologies for use in ophthalmology, in addition to certain rights to its proprietary riboswitch technology for use in gene editing in the eye.In return, MeiraGTx will receive an upfront payment of $75 million and will be eligible to receive over $400 million in total milestone payments in addition to tiered royalties on licensed products.“Ophthalmology is an emerging area of interest for Lilly,” said Andrew Adams, Lilly group vice president of Molecule Discovery.“We are excited to partner with MeiraGTx to bring transformative treatments to patients around the world suffering from eye diseases, starting with AAV-AIPL1, which has shown the unprecedented ability to restore vision in children who were born legally blind,” he added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MGTX">MGTX stock </a>jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:587/59;" src="data:image/png;base64,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" width="587" height="59" alt="MGTX's Sentiment Meter and Message Volume as of 10:18 a.m. ET on Nov. 10, 2025 | Source: Stocktwits"><figcaption>MGTX's Sentiment Meter and Message Volume as of 10:18 a.m. ET on Nov. 10, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock is undervalued.<stembedurl>https://stocktwits.com/waterlock/message/635582913</stembedurl>Another expressed hopes for FDA approval of AAV-AIPL1.<stembedurl>https://stocktwits.com/ErnieWorthing84/message/635572756</stembedurl>MGTX stock is up by 44% this year and by about 23% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ifrx-stock-soars-pre-market-after-experimental-drug-shows-promise-in-treating-chronic-skin-diseases/cLPcS62RE2E">IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

As part of its collaboration with Eli Lilly, MeiraGTx will grant it worldwide exclusive rights to its AAV-AIPL1 program for the treatment of Leber congenital amaurosis 4. 

iShares Russell 2000 BuyWrite ETF

Vanguard Russell 2000 Growth ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$9.49
Prev Close	$9.71
Open	$9.65
Dividend Yield	0.00%
50-Day Moving Average	$11.71
Beta	1.42
Avg. Volume	954,860.77
PE Ratio	13.45

52-Week High	$15.35
52-Week Low	$6.62
Market Capitalization	$911.45M
EPS (Annual)	-$1.42
Price to Book	4.15
Revenue Per Employee	$201,962.78

Feed

News

Sentiment

Earnings

Fundamentals

Info

MGTX Fundamentals